Mesoblast released FY2024 Q3 earnings on August 28 (EST), actual revenue USD 1.257M, actual EPS USD -0.2523

Brief Summary

Mesoblast’s Q3 FY2024 earnings report shows a revenue of $1.26 million and an EPS of -$0.2523, while the market expected a revenue of $4.683 million and the EPS was not expected to be negativeReuters+ 2.

Impact of The News

Financial Performance Analysis:

• Mesoblast reported lower-than-expected revenue and a negative EPS. The actual revenue was significantly below the market expectation of $4.683 millionReuters.
• The company recorded a net loss of $27.7 million for the quarterReuters+ 2.

Market Reaction:

• Following the earnings report, Mesoblast’s stock fell by 9.5% on the Australian Securities Exchange, indicating a negative market reaction to the earnings missReuters.

Peer Comparison:

• Compared to its peers in the biotech industry, such as Nvidia, which showed a strong financial performance with record-breaking revenues, Mesoblast’s financial results indicate a challenging business environment or operational issues.

Business Development Trend:

• The company’s net loss has widened compared to the previous fiscal year. Mesoblast needs to address these financial challenges to regain investor confidenceReuters+ 2.
• Analysts forecast a significant increase in revenue for the year 2026 to $69.2 million, suggesting that the company may have potential for recovery and growth in the medium termSimplywall.